Cypherpunk Technologies Inc., formerly Leap Therapeutics, reports developments tied to its transition from an oncology biotechnology company into an issuer with a digital asset treasury strategy focused on Zcash and its native coin, ZEC. The company changed its name in 2025, while continuing cancer research and development through a wholly owned subsidiary using the Leap Therapeutics name.
Recurring updates include ZEC treasury acquisitions, financing and capital-structure actions, board and leadership changes, quarterly financial results, and oncology program disclosures. The therapeutic pipeline referenced in company updates includes sirexatamab (DKN-01), a monoclonal antibody targeting DKK1, and FL-501, a monoclonal antibody targeting GDF-15.
Leap Therapeutics, in collaboration with BeiGene, announced the initiation of Part C of the DisTinGuish study, evaluating DKN-01 plus tislelizumab and chemotherapy in first-line gastric cancer patients. The study targets about 160 HER2-negative patients whose tumors express high DKK1 levels. Leap is also launching a second-line colorectal cancer trial with DKN-01 and bevacizumab, and supporting a trial in endometrial cancer with pembrolizumab. The company hosted an R&D Day to discuss these advancements and highlight strong preliminary results from previous trials.
Leap Therapeutics, Inc. (Nasdaq: LPTX) has announced a virtual R&D Day scheduled for July 12, 2022, at 12:00 pm ET. The event will feature the executive management team along with key opinion leaders discussing new data related to their lead candidate, DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Attendees can access a live webcast via the company's Investors page, where a replay will also be available.
Leap Therapeutics, Inc. (Nasdaq: LPTX) announced that initial clinical data from a Phase 1b/2a study of its anti-DKK1 antibody, DKN-01, will be presented at the ASCO Annual Meeting on June 6, 2022. The study evaluates DKN-01 as a monotherapy and in combination with docetaxel for metastatic castration-resistant prostate cancer (mCRPC). Key findings include no dose-limiting toxicities in any cohort and confirmed partial responses in all patients receiving the combination therapy, particularly in aggressive variant prostate cancer cases.
Leap Therapeutics (Nasdaq:LPTX) reported a net loss of $10.4 million for Q1 2022, up from $9.1 million in Q1 2021, driven by increased clinical trial costs. License revenues dropped to $0 due to the prior recognition of upfront payments. R&D expenses rose to $7.8 million, primarily from clinical trial costs and payroll increases. General and administrative expenses increased slightly to $2.8 million. As of March 31, 2022, the company held $103.2 million in cash and cash equivalents. Positive data from the DisTinGuish Study was presented, showing promising response rates in gastric cancer patients.
Leap Therapeutics (Nasdaq: LPTX) reported its financial results for the fourth quarter and year ended December 31, 2021. The company completed a $103.6 million public offering, yielding net proceeds of $96.8 million. Key clinical data from the DisTinGuish Study demonstrated promising results for DKN-01 in gastric cancer patients. Notably, the overall objective response rate (ORR) was 68%, with 90% in DKK1-high patients. Despite achieving clinical milestones, Leap incurred a net loss of $40.6 million, increasing from $27.5 million in 2020, primarily due to rising R&D expenses.
Leap Therapeutics (Nasdaq: LPTX) announced that its CEO, Douglas E. Onsi, will present a corporate overview at the Raymond James Institutional Investors Conference in Orlando from March 6-9, 2022. The presentation is scheduled for March 9 at 7:30 a.m. ET and will be available via live webcast on the company's Investors page. Leap focuses on developing targeted and immuno-oncology therapeutics, with its leading candidate, DKN-01, in trials for various cancers. A replay of the event will be accessible post-presentation.
Leica Biosystems has partnered with Leap Therapeutics (NASDAQ: LPTX) to create a companion diagnostic for detecting Dickkopf-related protein 1 (DKK1), a protein associated with poor cancer outcomes. This diagnostic will support the clinical development of Leap's DKN-01 therapy, a humanized monoclonal antibody currently in Phase 2 trials for gastric cancer. The test employs RNAscope™ technology to identify patients likely to benefit from DKN-01. This collaboration aims to enhance personalized cancer treatment based on biomarker profiles.
Leap Therapeutics (Nasdaq: LPTX), a biotechnology firm specializing in targeted and immuno-oncology therapies, will present a corporate overview at the B. Riley Securities Oncology Investor Conference on January 27, 2022, at 10:00 a.m. Eastern Time. The event will be virtual and accessible via the company’s website, where a replay will also be available. Leap's leading candidate, DKN-01, targets the Dickkopf-1 protein and is currently in clinical trials for various cancers. A partnership with BeiGene has been established for developing DKN-01 in Asia, Australia, and New Zealand.
Leap Therapeutics (Nasdaq: LPTX) announced that updated data from the DisTinGuish Phase 2a trial will be presented at the ASCO Gastrointestinal Cancers Symposium from January 20-22, 2022. The trial evaluates DKN-01, an anti-DKK1 antibody, combined with BeiGene's tislelizumab in patients with gastric and gastroesophageal junction cancer. Notable findings show promising efficacy in DKK1-high patients and improved safety tolerability. A conference call is scheduled for January 21, 2022, to discuss the results. The study is ongoing, focusing on both first-line and second-line therapies.
Leap Therapeutics (Nasdaq: LPTX) announced that its President and CEO, Douglas E. Onsi, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The presentation will be available on January 10 at 7:00 a.m. Eastern Time via their Investors page.
The company focuses on developing targeted and immuno-oncology therapeutics, with DKN-01 as their lead candidate currently in trials for various cancers.